<DOC>
	<DOCNO>NCT00389688</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) surgery may make tumor small reduce amount normal tissue need remove . Giving combination chemotherapy surgery may kill tumor cell remain surgery . It yet know whether combination chemotherapy effective surgery treat non-small cell lung cancer . PURPOSE : This randomized phase II trial study side effect pemetrexed disodium cisplatin compare well work give surgery treat patient stage IB stage II non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Pemetrexed Disodium Cisplatin Before After Surgery Treating Patients With Stage IB Stage II Non-Small Cell Lung Cancer That Can Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare tolerability ( term drug delivery toxicity ) neoadjuvant v adjuvant chemotherapy comprise cisplatin pemetrexed disodium patient resectable stage IB II non-small cell lung cancer . Secondary - Determine overall toxicity regimen patient . - Determine progression-free overall survival patient treat regimen . - Determine overall clinical response rate , pathologic complete response , resectability rate patient treat neoadjuvant chemotherapy . - Determine surgical morbidity mortality patient treat regimen . - Determine fraction patient adjuvant arm receives chemotherapy . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord institution , histological subtype ( squamous vs nonsquamous ) clinical stage ( IB v II ) . Patients randomize 1 2 treatment arm . - Arm I ( neoadjuvant chemotherapy ) : Patients receive cisplatin IV 3-6 hour pemetrexed disodium IV day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Four six week completion chemotherapy , patient undergo surgery . - Arm II ( adjuvant chemotherapy ) : Patients undergo surgery . Beginning 4-8 week surgery , patient receive cisplatin pemetrexed disodium arm I . After completion study treatment , patient follow periodically 5 year annually thereafter . PROJECTED ACCRUAL : A total 132 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IB II disease Resectable disease At least 1 measurable lesion No mediastinal involvement mediastinoscopy and/or positron emission tomography fludeoxyglucose F 18 scan No evidence metastatic disease PATIENT CHARACTERISTICS : WHO performance status 02 Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 10 g/dL Creatinine clearance ≥ 60 mL/min Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3.0 time ULN AST ALT ≤ 3.0 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignant disease , except follow : Basocellular carcinoma skin Adequately treat carcinoma situ cervix Lowgrade prostate cancer Other cancer patient diseasefree ≥ 5 year No congestive heart failure angina pectoris unless medically control No myocardial infarction within past 6 month No uncontrolled hypertension arrhythmia No active uncontrolled infection require antibiotic No illness medical condition would preclude study participation No preexisting motor sensory neurotoxicity ≥ grade 2 PRIOR CONCURRENT THERAPY : No prior surgery NSCLC No prior concurrent chemotherapy NSCLC No prior concurrent radiotherapy NSCLC No concurrent immunotherapy No concurrent target agent No concurrent hormonal cancer therapy No concurrent routine colonystimulating factor ( e.g. , prophylactic filgrastim [ GCSF ] ) No aspirin nonsteroidal antiinflammatory drug within 5 day chemotherapy No concurrent experimental treatments No concurrent anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
</DOC>